ASCENT-03 Study Presented by Sara Tolaney, MD, MPH
Dr. Sara Tolaney details research in The New England Journal of Medicine showing the ADC sacituzumab govitecan improved outcomes for patients with advanced triple-negative #BreastCancer ineligible for immune checkpoint inhibitors.
Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships ...
